Reviva Pharmaceuticals Holdings (RVPH) Total Liabilities (2018 - 2026)
Reviva Pharmaceuticals Holdings (RVPH) posted Total Liabilities of $6.1 million for Q1 2026, down 15.89% sequentially from $7.3 million in Q4 2025, and down 46.96% YoY from $11.5 million in Q1 2025.
Reviva Pharmaceuticals Holdings (RVPH) Total Liabilities (2018 - 2026) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported Total Liabilities for 9 years, with the latest figure at $6.1 million in Q1 2026.
- Quarterly Total Liabilities fell 46.96% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.1 million (down 46.96% YoY) and the FY2025 annual result came in at $7.3 million, down 50.47% from the prior year.
- Total Liabilities retreated to $6.1 million in Q1 2026 per RVPH's latest filing, from $7.3 million in the prior quarter.
- Over five years, Total Liabilities peaked at $18.2 million in Q3 2023 and troughed at $3.9 million in Q1 2022.
- A 5-year average of $11.5 million and a median of $11.5 million in 2025 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities jumped 299.19% in 2022, then slumped 50.47% in 2025.
- Over 5 years, Total Liabilities stood at $10.5 million in 2022, then surged by 70.78% to $18.0 million in 2023, then decreased by 18.3% to $14.7 million in 2024, then plunged by 50.47% to $7.3 million in 2025, then dropped by 15.89% to $6.1 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $6.1 million, $7.3 million, and $9.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Reviva Pharmaceuticals Holdings | 6.74 Mn | 6.74 Mn | - | 5.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.93 Mn |
| Mar 31, 2026 | 6.12 Mn |
| Dec 31, 2025 | 7.28 Mn |
| Sep 30, 2025 | 9.78 Mn |
| Jun 30, 2025 | 12.09 Mn |
| Mar 31, 2025 | 11.54 Mn |
| Dec 31, 2024 | 14.69 Mn |
| Sep 30, 2024 | 17.61 Mn |
| Jun 30, 2024 | 14.09 Mn |
| Mar 31, 2024 | 14.84 Mn |
| Dec 31, 2023 | 17.98 Mn |
| Sep 30, 2023 | 18.20 Mn |
| Jun 30, 2023 | 13.66 Mn |
| Mar 31, 2023 | 11.29 Mn |
| Dec 31, 2022 | 10.53 Mn |
| Sep 30, 2022 | 6.49 Mn |
| Jun 30, 2022 | 4.58 Mn |
| Mar 31, 2022 | 3.91 Mn |
| Sep 30, 2021 | 1.62 Mn |
| Jun 30, 2021 | 2.01 Mn |